Clinical management of the painful diabetic neuropathies

Journal of the Royal College of Physicians of London

Volumn 34, Issue 4, 2000, Pages 340-343

  Boulton, Andrew J M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CHLORPROMAZINE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUPHENAZINE; GABAPENTIN; IMIPRAMINE; MEXILETINE; NEUROLEPTIC AGENT; THIOCTIC ACID; TRAMADOL; TRANDOLAPRIL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; ANALGESIA; CLINICAL TRIAL; CONSTIPATION; DIABETIC NEUROPATHY; DROWSINESS; FOOT ULCER; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; NAUSEA; SENSORY NEUROPATHY; SHORT SURVEY; SIDE EFFECT; SPINAL CORD STIMULATION; SYMPTOM; VERTIGO; XEROSTOMIA;

ACETIC ACIDS; AMINES; ANALGESICS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANECARBOXYLIC ACIDS; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; GAMMA-AMINOBUTYRIC ACID; HUMANS; PAIN;

EID: 0033870469     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin North Am 1998;82:909-29.
2. Ziegler D. Pharmacological treatment of painful diabetic neuropathy. In: Veves A (ed). Clinical management of diabetic neuropathy. Totawa, NJ: Humana Press, 1998:147-68.
3. Boulton AJM. Current and emerging treatments for the diabetic neuropathies. Diabetes Rev 1999;7:379-86.
4. Archer AG, Watkins PJ, Thomas PK, Sharma AK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983;46:491-9.
5. Diabetes Control and Complications Trial Research Group. The effect of Intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
6. UK Prospective Diabetes Study 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
7. Woolf O, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet 1999;353: 1959-64.
8. McQuay H, Tramer M, Nye BA, Carroll D, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68: 217-27.
9. Young RJ, Clarke BF. Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs. Diabet Med 1985;2:363-6.
10. Backonja M, Beydoun A, Edwards KR, Schwartz SL, et al. Gabapentin for the symptomatic treatment of peripheral neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
11. Jarvis B, Coukell AJ. Mexiletine: a review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.
12. Harati Y, Gooch C, Swenson M, Edelman S, et al. Double-blind randomised trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50:1842-6.
13. Carrington AL, Litchfield JE. The aldose reductase pathway and non-enzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the twentieth century. Diabetes Rev 1999;7:275-99.
14. Ziegler D, Hanefeld M, Ruhnau KJ, Hasch H, et al. Treatment of symptomatic diabetic neuropathy with the anti-oxidant α-lipoic acid: a 7-month randomised controlled trial. Diabetes Care 1999;20: 369-73.
15. Malik RA, Williamson S, Abbott CA, et al. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352:1978-81.